Results 11 to 20 of about 194,657 (287)

Irinotecan Upregulates Fibroblast Growth Factor Receptor 3 Expression in Colorectal Cancer Cells, Which Mitigates Irinotecan-Induced Apoptosis [PDF]

Translational Oncology, 2017
BACKGROUND: Irinotecan (IRI) is an integral part of colorectal cancer (CRC) therapy, but response rates are unsatisfactory and resistance mechanisms are still insufficiently understood.
Zeynep N. Erdem, Stefanie Schwarz, Daniel Drev, Christine Heinzle, Andrea Reti, Petra Heffeter, Xenia Hudec, Klaus Holzmann, Bettina Grasl-Kraupp, Walter Berger, Michael Grusch, Brigitte Marian   +11 more
doaj   +2 more sources

Fibroblast growth factor receptor 3 mutation promotes HSPB6-mediated cuproptosis in hypochondroplasia by impairing chondrocyte autophagy [PDF]

Journal of Orthopaedic Translation
Background: Hypochondroplasia (HCH) is a prevalent form of dwarfism linked to mutations in the fibroblast growth factor receptor 3 (FGFR3) gene, causing missense alterations.
Jing Chen, Dan He, Chengrun Yuan, Na Li, Baohong Shi, Conway Niu, Jiangfei Yang, Liangkai Zheng, Lin Che, Ren Xu   +9 more
doaj   +1 more source

Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. [PDF]

Mol Cancer Ther, 2013
Abstract Activating mutations of fibroblast growth factor receptor-3 (FGFR3) have been described in approximately 75% of low-grade papillary bladder tumors. In muscle-invasive disease, FGFR3 mutations are found in 20% of tumors, but overexpression of FGFR3 is observed in about half of cases.
Gust KM, McConkey DJ, Awrey S, Hegarty PK, Qing J, Bondaruk J, Ashkenazi A, Czerniak B, Dinney CP, Black PC.   +9 more
europepmc   +5 more sources

A novel S269C mutation in fibroblast growth factor receptor 3 in a Japanese child with hypochondroplasia. [PDF]

Hum Genome Var, 2018
Functionally activating mutations in fibroblast growth factor receptor 3 (FGFR3) can cause four types of autosomal dominant skeletal dysplasia with short-limbed dwarfism that include the mildest phenotype, hypochondroplasia (HCH). A novel mutation (c.805A>T, p.S269C) was identified in a Japanese infant with HCH through direct sequencing of all FGFR3 ...
Takahashi I, Kondo D, Oyama C, Yano T, Tamura H, Noguchi A, Takahashi T.   +6 more
europepmc   +5 more sources

Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3 [PDF]

Molecular Biology of the Cell, 2011
Fibroblast growth factor receptor 3 (FGFR3) is a major negative regulator of bone growth that inhibits the proliferation and differentiation of growth plate chondrocytes. Activating mutations of its c isoform cause dwarfism in humans; somatic mutations can drive oncogenic transformation in multiple myeloma and bladder cancer.
Catherine Degnin, Melanie B. Laederich, William A. Horton   +2 more
openalex   +3 more sources

Inhibition of fibroblast growth factor receptor 3-dependent lung adenocarcinoma with a human monoclonal antibody

Disease Models & Mechanisms, 2016
Activating mutations in fibroblast growth factor receptor 3 (FGFR3) have been identified in multiple types of human cancer and in congenital birth defects.
Yongjun Yin, Xiaodi Ren, Craig Smith, Qianxu Guo, Maria Malabunga, Ilhem Guernah, Yiwei Zhang, Juqun Shen, Haijun Sun, Nabil Chehab, Nick Loizos, Dale L. Ludwig, David M. Ornitz   +12 more
doaj   +2 more sources

In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3 [PDF]

International Journal of Nanomedicine, 2017
Gyoyeon Hwang,1,2,* Hyeonhye Kim,1,* Hojong Yoon,1 Chiman Song,1 Dong-Kwon Lim,3 Taebo Sim,1,3 Jiyeon Lee1,2 1Chemical Kinomics Research Center, Materials and Life Science Research Division, Korea Institute of Science and Technology, Seoul, 2Bio-Med ...
Hwang G, Kim H, Yoon H, Song C, Lim D, Sim T, Lee J   +6 more
doaj   +2 more sources

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism

PLoS ONE, 2022
This ad hoc analysis of a previously conducted phase 3 head-to-head comparison study of evocalcet and cinacalcet in secondary hyperparathyroidism patients undergoing maintenance hemodialysis evaluated the efficacy and safety of combined once-daily oral ...
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa, Tadao Akizawa   +5 more
doaj   +2 more sources

Fibroblast growth factor receptor 3 deficiency does not impair the osteoanabolic action of parathyroid hormone on mice [PDF]

Journal of Orthopaedic Translation, 2016
Yangli Xie, Wei Xu, Siru Zhou, Junlan Huang, Xiaolan Du, Lin Chen   +5 more
doaj   +2 more sources

Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth [PDF]

Cell, 1996
Endochondral ossification is a major mode of bone that occurs as chondrocytes undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and ...
Ann Kuo, Chu-Xia Deng, Anthony Wynshaw-Boris, Fen Zhou, Philip Leder   +4 more
openaire   +3 more sources